Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Q32 Bio disclosed additional Week 36 results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata. The study showed clinically meaningful hair regrowth, with responses seen across patient subgroups, supporting a move toward registrational development. Safety was generally well tolerated
Q32 Bio Inc. will present 36-week results from its Phase 2a SIGNAL-AA Part B trial of bempikibart in severe alopecia areata at the EADV Congress in Vienna on Sept. 30, 2026. The data will include early findings from a 16-week off-drug period, indicating hair regrowth that persisted after treatment stopped.